Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX007 Long-Term Extension in LC-FAOD
NCT02214160Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Dec 2014
- Primary completion
- Dec 2020
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of triheptanoin in Long Chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Annualized LC-FAOD Major Clinical Events (MCEs) Rate at 2072 days and Number of Participants With Treatment-Emergent Adverse Events at 2072 days. Started Dec 2014; status: completed.
02
Drugs
triheptanoin
03
Conditions
Long Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Beyond the preview
Go deeper on NCT02214160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214160.